The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations

Research output: Contribution to journalReview articlepeer-review

Standard

The Next Frontier of Regulatory T Cells : Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. / Terry, Lauren V; Oo, Ye Htun.

In: Frontiers in immunology, Vol. 11, 565518, 23.09.2020.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{e896234fb8e046469ba0cf1389bbb08b,
title = "The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations",
abstract = "Regulatory T cells (Tregs) are crucial in maintaining tolerance. Hence, Treg immunotherapy is an attractive therapeutic option in autoimmune diseases and organ transplantations. Currently, autoimmune diseases do not have a curative treatment and transplant recipients require life-long immunosuppression to prevent graft rejection. There has been significant progress in understanding polyclonal and antigen-specific Treg biology over the last decade. Clinical trials with good manufacturing practice (GMP) Treg cells have demonstrated safety and early efficacy of Treg therapy. GMP Treg cells can also be tracked following infusion. In order to improve efficacy of Tregs immunotherapy, it is necessary that Tregs migrate, survive and function at the specific target tissue. Application of antigen specific Tregs and maintaining cells' suppressive function and survival with low dose interleukin-2 (IL-2) will enhance the efficacy and longevity of infused GMP-grade Tregs. Notably, stability of Tregs in the local tissue can be manipulated by understanding the microenvironment. With the recent advances in GMP-grade Tregs isolation and antigen-specific chimeric antigen receptor (CAR)-Tregs development will allow functionally superior cells to migrate to the target organ. Thus, Tregs immunotherapy may be a promising option for patients with autoimmune diseases and organ transplantations in near future.",
keywords = "regulatory T cell, liver transplant, autoimmune liver diseases, antigen specific, recruitment, tolerance, polyclonal",
author = "Terry, {Lauren V} and Oo, {Ye Htun}",
note = "Copyright {\textcopyright} 2020 Terry and Oo.",
year = "2020",
month = sep,
day = "23",
doi = "10.3389/fimmu.2020.565518",
language = "English",
volume = "11",
journal = "Frontiers in immunology",
issn = "1664-3224",
publisher = "Frontiers",

}

RIS

TY - JOUR

T1 - The Next Frontier of Regulatory T Cells

T2 - Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations

AU - Terry, Lauren V

AU - Oo, Ye Htun

N1 - Copyright © 2020 Terry and Oo.

PY - 2020/9/23

Y1 - 2020/9/23

N2 - Regulatory T cells (Tregs) are crucial in maintaining tolerance. Hence, Treg immunotherapy is an attractive therapeutic option in autoimmune diseases and organ transplantations. Currently, autoimmune diseases do not have a curative treatment and transplant recipients require life-long immunosuppression to prevent graft rejection. There has been significant progress in understanding polyclonal and antigen-specific Treg biology over the last decade. Clinical trials with good manufacturing practice (GMP) Treg cells have demonstrated safety and early efficacy of Treg therapy. GMP Treg cells can also be tracked following infusion. In order to improve efficacy of Tregs immunotherapy, it is necessary that Tregs migrate, survive and function at the specific target tissue. Application of antigen specific Tregs and maintaining cells' suppressive function and survival with low dose interleukin-2 (IL-2) will enhance the efficacy and longevity of infused GMP-grade Tregs. Notably, stability of Tregs in the local tissue can be manipulated by understanding the microenvironment. With the recent advances in GMP-grade Tregs isolation and antigen-specific chimeric antigen receptor (CAR)-Tregs development will allow functionally superior cells to migrate to the target organ. Thus, Tregs immunotherapy may be a promising option for patients with autoimmune diseases and organ transplantations in near future.

AB - Regulatory T cells (Tregs) are crucial in maintaining tolerance. Hence, Treg immunotherapy is an attractive therapeutic option in autoimmune diseases and organ transplantations. Currently, autoimmune diseases do not have a curative treatment and transplant recipients require life-long immunosuppression to prevent graft rejection. There has been significant progress in understanding polyclonal and antigen-specific Treg biology over the last decade. Clinical trials with good manufacturing practice (GMP) Treg cells have demonstrated safety and early efficacy of Treg therapy. GMP Treg cells can also be tracked following infusion. In order to improve efficacy of Tregs immunotherapy, it is necessary that Tregs migrate, survive and function at the specific target tissue. Application of antigen specific Tregs and maintaining cells' suppressive function and survival with low dose interleukin-2 (IL-2) will enhance the efficacy and longevity of infused GMP-grade Tregs. Notably, stability of Tregs in the local tissue can be manipulated by understanding the microenvironment. With the recent advances in GMP-grade Tregs isolation and antigen-specific chimeric antigen receptor (CAR)-Tregs development will allow functionally superior cells to migrate to the target organ. Thus, Tregs immunotherapy may be a promising option for patients with autoimmune diseases and organ transplantations in near future.

KW - regulatory T cell

KW - liver transplant

KW - autoimmune liver diseases

KW - antigen specific

KW - recruitment

KW - tolerance

KW - polyclonal

U2 - 10.3389/fimmu.2020.565518

DO - 10.3389/fimmu.2020.565518

M3 - Review article

C2 - 33072105

VL - 11

JO - Frontiers in immunology

JF - Frontiers in immunology

SN - 1664-3224

M1 - 565518

ER -